Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 954

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

Open access
Krejcik, Jakub, Casneuf, Tineke, Nijhof, Inger S., Verbist, Bie, Bald, Jaime, Plesner, Torben, Syed, Khaja, Liu, Kevin, van de Donk, Niels W. C. J., Weiss, Brendan M., Ahmadi, Tahamtan, Lokhorst, Henk M., Mutis, Tuna, Sasser, A. Kate·2016·Blood
DOI 10.1182/blood-2015-12-687749
Open this paper in CoChat — free account

Abstract

Key Points: CD38-expressing immunosuppressive regulatory T and B cells and myeloid-derived suppressor cells were sensitive to daratumumab treatment. Cytotoxic T-cell number, activation, and clonality increased after daratumumab treatment in heavily pretreated relapsed and refractory MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2015-12-687749

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 25

  1. Harousseau, 2010, Ten years of improvement in the management of multiple myeloma: 2000-2010., Clin Lymphoma Myeloma Leuk, 10, 424, 10.3816/CLML.2010.n.076 · DOI
  2. Kastritis, 2009, Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)., Leukemia, 23, 1152, 10.1038/leu.2008.402 · DOI · Paper page
  3. Kumar, 2008, Improved survival in multiple myeloma and the impact of novel therapies., Blood, 111, 2516, 10.1182/blood-2007-10-116129 · DOI · Paper page
  4. Kumar, 2012, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study., Leukemia, 26, 149, 10.1038/leu.2011.196 · DOI · Paper page
  5. Dosani, 2015, The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies., Blood Cancer J, 5, e306, 10.1038/bcj.2015.32 · DOI
  6. Ray, 2015, Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells., Leukemia, 29, 1441, 10.1038/leu.2015.11 · DOI · Paper page
  7. Deaglio, 2007, Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression., J Exp Med, 204, 1257, 10.1084/jem.20062512 · DOI · Paper page
  8. Zarek, 2008, A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells., Blood, 111, 251, 10.1182/blood-2007-03-081646 · DOI · Paper page
  9. Binsfeld, 2014, Cellular immunotherapy in multiple myeloma: lessons from preclinical models., Biochim Biophys Acta, 1846, 392
  10. Feyler, 2009, CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden., Br J Haematol, 144, 686, 10.1111/j.1365-2141.2008.07530.x · DOI
  11. Roeven, 2014, Immunotherapeutic approaches to treat multiple myeloma., Hum Vaccin Immunother, 10, 896, 10.4161/hv.27380 · DOI
  12. Lin, 2004, Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma., Am J Clin Pathol, 121, 482, 10.1309/74R4TB90BUWH27JX · doi:10.1309/74r4tb90buwh27jx · Paper page
  13. Santonocito, 2004, Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients., Leuk Res, 28, 469, 10.1016/j.leukres.2003.09.015 · DOI
  14. Karakasheva, 2015, CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer., Cancer Res, 75, 4074, 10.1158/0008-5472.CAN-14-3639 · DOI · Paper page
  15. Flores-Borja, 2013, CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation., Sci Transl Med, 5, 173ra23, 10.1126/scitranslmed.3005407 · DOI · Paper page
  16. de Weers, 2011, Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors., J Immunol, 186, 1840, 10.4049/jimmunol.1003032 · DOI · Paper page
  17. McKeage, 2016, Daratumumab: first global approval., Drugs, 76, 275, 10.1007/s40265-015-0536-1 · DOI · Paper page
  18. Rajkumar, 2011, Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1., Blood, 117, 4691, 10.1182/blood-2010-10-299487 · DOI · Paper page
  19. van de Donk, 2016, Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma., Blood, 127, 681, 10.1182/blood-2015-10-646810 · DOI · Paper page
  20. Görgün, 2013, Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans., Blood, 121, 2975, 10.1182/blood-2012-08-448548 · DOI · Paper page
  21. Robins, 2012, Ultra-sensitive detection of rare T cell clones., J Immunol Methods, 375, 14, 10.1016/j.jim.2011.09.001 · DOI · Paper page
  22. Royston, 1995, Remark AS R94: A remark on Algorithm AS 181: the W test for normality., J Royal Stat Society, Series C (Applied Stats), 44, 547
  23. Kotsakis, 2012, Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples., J Immunol Methods, 381, 14, 10.1016/j.jim.2012.04.004 · DOI · Paper page
  24. Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma., N Engl J Med, 372, 311, 10.1056/NEJMoa1411087 · DOI · Paper page
  25. Lee, 2013, Novel antibodies targeting immune regulatory checkpoints for cancer therapy., Br J Clin Pharmacol, 76, 233, 10.1111/bcp.12164 · DOI

Cited by

See all 954

Metadata

Authors
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., Ahmadi, T., Lokhorst, H. M., Mutis, T., & Sasser, A. K.
Venue
Blood
Publisher
American Society of Hematology
Published
2016-07-21
Volume
128
Issue
3
Pages
384-394
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2015-12-687749
OpenAlex
W2400276917
Cited by
954
References
8
FWCI
61.62
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2015-12-687749
The paper
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., Ahmadi, T., Lokhorst, H. M., Mutis, T., & Sasser, A. K. (2016). Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. https://doi.org/10.1182/blood-2015-12-687749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.